Skip to content

Corporate Sponsored Program – Takeda: Reducing the need for Parenteral Support (PS) in patients with Short Bowel Syndrome (SBS) through GATTEX® (Teduglutide)

2:00 PM - 3:30 PM

DESCRIPTION
SBS is a serious and chronic malabsorption disorder resulting from physical loss and functional deficiency of portions of the intestine, primarily due to surgical resection. Treatment goals for SBS patients include reducing or eliminating the need for PS and promoting intestinal adaptation. This program will discuss GATTEX, a GLP-2 analog, its mechanism of action, and its role in reducing time spent on PS.

LEARNING OBJECTIVES

  1. Review SBS disease management and unmet needs
  2. Understand the role of GATTEX in improving absorptive capacity and reducing PS needs in SBS management
  3. Highlight considerations for initiating GATTEX as a long-term treatment that can possibly reduce time on PS, which may allow patients more freedom for other activities


    FACULTY

    Gabby Gardner, RD, Memorial Hermann-Texas Medical Center, Houston, TX

    CE NOT AVAILABLE

    Takeda